PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2021
CASE
AstraZeneca

AstraZeneca corporate medicines webpage: inaccurate black triangle status breached Clause 26.2

A clinician complained that AstraZeneca’s public corporate medicines list showed incorrect/missing black triangle symbols and omitted Imjudo. The Panel found a breach…

Teva ⭐ Case of the Week

Teva UK Ltd: Guidelines in Practice insert on switching to CFC-free beclometasone inhalers (Qvar) found misleading and promotional

A GP challenged a Teva-supported insert distributed with Guidelines in Practice. The Panel found it was effectively a paid promotional insert for…

2008
CASE
GlaxoSmithKline

GSK diabetes partnership contract and voicemail implied funding was linked to Avandamet protocol placement

An anonymous GSK employee challenged a diabetes service partnership with a primary healthcare service company. A voicemail and contract implied funding was…

2008
CASE
Pfizer

Pfizer: Toviaz journal advertisementsβ€”misleading comparative efficacy claims vs tolterodine ER

A GP challenged Pfizer’s Toviaz ads comparing fesoterodine 8mg with tolterodine ER. The PMCPA found the comparative claims misleading and unsubstantiated, and…

2008
CASE
AUTH/2143/7/08 Syner-Med

Syner-Med detail aid ruled misleading on Ferinject dosing claims (AUTH/2143/7/08)

A nurse alleged she was told Ferinject was safe and could be given as 1,000mg in 15 minutes. The Panel found insufficient…

2008
CASE
AUTH/2123/5/08 Sandoz

AUTH/2123/5/08: General practitioner v Sandoz – promotional email sent via agency (no breach)

A GP complained about large promotional emails sent on Sandoz’s behalf. The Panel found the email was promotional but could not determine…

2009
CASE
AUTH/2208/2/09 Gilead Sciences ⭐ Case of the Week

AUTH/2208/2/09: Health professional v Gilead Sciences – unsolicited email about fellowship programme (no breach)

A health professional complained about an unsolicited email advertising a Gilead fellowship programme. The Panel found the email was non-promotional and ruled…

2009
CASE
AUTH/2199/1/09 Roche Products

Novartis v Roche: Bondronat leavepieceβ€”misleading indirect comparisons and renal safety messaging (AUTH/2199/1/09)

Roche’s Bondronat leavepiece was ruled misleading for indirect cross-trial graphs, exaggerated β€œrenal safety reassurance” claims, and unclear interim poster data. Multiple Clause…

2008
CASE
AUTH/2184/11/08 Pfizer

Pfizer: Lipitor journal ad – economic modelling percentages presented as clinical absolutes (AUTH/2184/11/08)

A Lipitor journal ad cited economic modelling (β€œ37%” vs β€œ82%”) on cholesterol target attainment. PMCPA found the bold percentages misleading and not…

2008
CASE
AUTH/2174/10/08 Merck Serono

AUTH/2174/10/08: Anonymous v Merck Serono β€” fertility nurse meeting hospitality and alleged off-label concerns (No breach)

Anonymous complaint alleged inappropriate entertainment/hospitality, biased sponsorship of delegates, and suspected off-label selling of Pergoveris at a fertility nurse meeting. PMCPA ruled…

2008
CASE
AUTH/2158/8/08 Sanofi

AUTH/2158/8/08: Pharmacist v Sanofi-Aventis (Acomplia reply-paid card fulfilment) – No breach

A pharmacist said Sanofi-Aventis didn’t fulfil a reply-paid card request for Acomplia clinical papers and promotional items. Panel and Appeal Board found…

2009
CASE
AUTH/2248/7/09 Astellas Pharma ⭐ Case of the Week

AUTH/2248/7/09: Member of the public v Astellas Pharma (conduct of representatives) – No breach

Complaint alleged lunch meetings with no educational content and inflated stand-meeting contacts. Panel found no evidence to support allegations and ruled no…

2009
CASE
AUTH/2225/4/09 Astellas Pharma

AUTH/2225/4/09: Anonymous doctor v Astellas β€” summer school venue and hospitality (no breach)

Anonymous doctor alleged Astellas’ transplant summer school used a lavish venue and linked to aggressive promotion. Panel found hospitality near the limit…

2009
CASE
AUTH/2277/11/09 Flynn Pharma

AUTH/2277/11/09: PCT Prescribing Advisor v Flynn Pharma (Distaclor MR email) – No breach

A PCT prescribing advisor challenged a GP email promoting Distaclor MR β€œstarter packs” post-flu, citing antimicrobial stewardship and C. difficile risk. Panel…

2009
CASE
AUTH/2280/11/09 Boehringer Ingelheim

AUTH/2280/11/09: Prescribing Advisor v Boehringer Ingelheim (Pradaxa) – alleged promotion of unlicensed half-dose (No breach)

A prescribing advisor alleged reps advised surgeons to use Pradaxa at an unlicensed β€œhalf dose”. The Panel could not determine what transpired…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training